Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation

Journal of Cardiology

Volumn 69, Issue 6, 2017, Pages 868-876

  Bengtson, Lindsay G S ^a   Lutsey, Pamela L ^b   Chen, Lin Y ^c   MacLehose, Richard F ^b   Alonso, Alvaro ^d  

^a Health Economics and Outcomes Research   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Atrial fibrillation; Gastrointestinal bleeding; Intracranial bleeding; Oral anticoagulants; Stroke

Indexed keywords

DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT RISK; PELVIS FRACTURE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; CHEMICALLY INDUCED; COMPARATIVE STUDY; MIDDLE AGED; MYOCARDIAL INFARCTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DABIGATRAN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RIVAROXABAN; WARFARIN;

EID: 85007270705     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2016.08.010     Document Type: Article

References (31)

1. [1] Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., Das, S.R., De Ferranti, S., Després, J.P., Fullerton, H.J., Howard, V.J., Huffman, M.D., Isasi, C.R., Jiménez, M.C., Judd, S.E., et al. Heart disease and stroke statistics – 2016 update: a report from the American Heart Association. Circulation 133 (2016), e38–e360.
2. [2] January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cigarroa, J.E., Cleveland, J.C., Conti, J.B., Ellinor, P.T., Ezekowitz, M.D., Field, M.E., Murray, K.T., Sacco, R.L., Stevenson, W.G., Tchou, P.J., Tracy, C.M., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 130 (2014), e199–e267.
3. [3] Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
4. [4] Granger, C.B., Alexander, J.H., McMurray, J.J.V., Lopes, R.D., Hylek, E.M., Hanna, M., Al-Khalidi, H.R., Ansell, J., Atar, D., Avezum, A., Bahit, M.C., Diaz, R., Easton, J.D., Ezekowitz, J.A., Flaker, G., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
5. [5] Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W., Breithardt, G., Halperin, J.L., Hankey, G.J., Piccini, J.P., Becker, R.C., Nessel, C.C., Paolini, J.F., Berkowitz, S.D., Fox, K.A.A., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
6. [6] Giugliano, R.P., Ruff, C.T., Braunwald, E., Murphy, S.A., Wiviott, S.D., Halperin, J.L., Waldo, A.L., Ezekowitz, M.D., Weitz, J.I., Špinar, J., Ruzyllo, W., Ruda, M., Koretsune, Y., Betcher, J., Shi, M., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
7. [7] Morimoto, T., Crawford, B., Wada, K., Ueda, S., Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: a network meta-analysis with the adjustment for the possible bias from open studies. J Cardiol 66 (2015), 466–474.
8. [8] Romanelli, R.J., Nolting, L., Dolginsky, M., Kym, E., Orrico, K.B., Dabigatran versus warfarin for atrial fibrillation in real-world clinical practice: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 9 (2016), 126–134.
9. [9] Ezekowitz, M.D., Wallentin, L., Connolly, S.J., Parekh, A., Chernick, M.R., Pogue, J., Aikens, T.H., Yang, S., Reilly, P.A., Lip, G.Y., Yusuf, S., RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 122 (2010), 2246–2253.
10. [10] Mahaffey, K.W., Wojdyla, D., Hankey, G.J., White, H.D., Nessel, C.C., Piccini, J.P., Patel, M.R., Berkowitz, S.D., Becker, R.C., Halperin, J.L., Singer, D.E., Califf, R.M., Fox, K.A., Breithardt, G., Hacke, W., Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med 158 (2013), 861–868.
11. [11] Bouillon, K., Bertrand, M., Maura, G., Blotiere, P.O., Ricordeau, P., Zureik, M., Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol 2 (2015), e150–e159.
12. [12] Jensen, P.N., Johnson, K., Floyd, J., Heckbert, S.R., Carnahan, R., Dublin, S., A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf 21:Suppl. 1 (2012), 141–147.
13. [13] Piccini, J.P., Hammill, B.G., Sinner, M.F., Jensen, P.N., Hernandez, A.F., Heckbert, S.R., Benjamin, E.J., Curtis, L.H., Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries: 1993–2007. Circ Cardiovasc Qual Outcomes 5 (2012), 85–93.
14. [14] Naccarelli, G.V., Johnston, S.S., Dalal, M., Lin, J., Patel, P.P., Rates and implications for hospitalization of patients ≥65 year of age with atrial fibrillation/flutter. Am J Cardiol 109 (2012), 543–549.
15. [15] Garg, R.K., Glazer, N.L., Wiggins, K.L., Newton, K.M., Thacker, E.L., Smith, N.L., Siscovick, D.S., Psaty, B.M., Heckbert, S.R., Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy data. Pharmacoepidemiol Drug Saf 20 (2011), 313–316.
16. [16] Andrade, S.E., Harrold, L.R., Tjia, J., Cutrona, S.L., Saczynski, J.S., Dodd, K.S., Goldberg, R.J., Gurwitz, J.H., A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf 21:Suppl. 1 (2012), 100–128.
17. [17] Kiyota, Y., Schneeweiss, S., Glynn, R.J., Cannuscio, C.C., Avorn, J., Solomon, D.H., Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 148 (2004), 99–104.
18. [18] Wahl, P.M., Rodgers, K., Schneeweiss, S., Gage, B.F., Butler, J., Wilmer, C., Nash, M., Esper, G., Gitlin, N., Osborn, N., Short, L.J., Bohn, R.L., Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf 19 (2010), 596–603.
19. [19] Cunningham, A., Stein, C.M., Chung, C.P., Daugherty, J.R., Smalley, W.E., Ray, W.A., An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 20 (2011), 560–566.
20. [20] Baxter, N.N., Haberman, E.B., Tepper, J.E., Durham, S.B., Virnig, B.A., Risk of pelvic fractures in older women following pelvic irradiation. JAMA 294 (2005), 2587–2593.
21. [21] Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.C., Saunders, L.D., Beck, C.A., Feasby, T.E., Ghali, W.A., Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43 (2005), 1130–1139.
22. [22] Schneeweiss, S., Rassen, J.A., Glynn, R.J., Avorn, J., Mogun, H., Brookhart, M.A., High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20 (2009), 512–522.
23. [23] Rassen JA, Doherty M, Huang W, Schneeweiss S. Pharmacoepidemiology toolbox. Boston, MA. http://www.drugepi.org (Accessed September 6, 2016).
24. [24] Parsons LS. SUGI 26: Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Available from: www2.sas.com/proceedings/sugi26//p214-26.pdf (Accessed September 6, 2016).
25. [25] Graham, D.J., Reichman, M.E., Wernecke, M., Zhang, R., Southworth, M.R., Levenson, M., Sheu, T.C., Mott, K., Goulding, M.R., Houstoun, M., MaCurdy, T.E., Worrall, C., Kelman, J.A., Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 131 (2015), 157–164.
26. [26] Hernandez, I., Baik, S.H., Piñera, A., Zhang, Y., Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 175 (2015), 18–24.
27. [27] Lauffenburger, J.C., Farley, J.F., Gehi, A.K., Rhoney, D.H., Brookhart, M.A., Fang, G., Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc, 4, 2015, e001798.
28. [28] Villines, T.C., Schnee, J., Fraeman, K., Siu, K., Reynolds, M.W., Collins, J., Schwartzman, E., A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 114 (2015), 1290–1298.
29. [29] Seeger, J.D., Bykov, K., Bartels, D.B., Huybrechts, K., Zint, K., Schneeweiss, S., Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 114 (2015), 1277–1289.
30. [30] Nelson, W.W., Desai, S., Damaraju, C.V., Lu, L., Fields, L.E., Wildgoose, P., Schein, J.R., International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation. Curr Med Res Opin 30 (2014), 2437–2442.
31. [31] Nishino, M., Okamoto, N., Tanaka, A., Mori, N., Hara, M., Yano, M., Makino, N., Egami, Y., Shutta, R., Tanouchi, J., Different risk factors for bleeding and discontinuation between dabigatran and rivaroxaban. J Cardiol 68 (2016), 156–160.